Skip to content
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact
Westlake BioPartners
  • People
  • Portfolio
  • About
  • News
  • Contact

Latest News & Insights

Stay Up to Date with Our Community

Featured

Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

May 14, 2025
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental...
Read More
Loading...

Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance of Its First-in-Class, IV-administered Gene Therapy for STXBP1 Developmental and Epileptic Encephalopathy

May 14, 2025
Capsida Presents New GLP Toxicology Data Supporting Recent FDA IND Clearance...
Read More
Portfolio News

Capsida to Present Progress Updates at the ASGCT Annual Meeting, Including NHP GLP Toxicology Study Results for its Potential First-in-Class STXBP1 Developmental and Epileptic Encephalopathy Program (CAP-002 STXBP1-DEE)

April 28, 2025
Capsida will also present data from its potential best-in-class programs for...
Read More
Portfolio News

Capsida Presents New Data from GLP Toxicology Study in NHPs Demonstrating Potential Best-in-Class Profile of CAP-003 in Patients with Parkinson’s Disease Associated with GBA Mutations (PD-GBA)

April 3, 2025
GCase elevations meaningfully exceeding efficacy threshold, well-tolerated safety profile, and IV-administration...
Read More
Portfolio News

Neuron23 Announces Publication in PNAS Highlighting the Important Role of TYK2 in Neuroimmunology

March 25, 2025
Neuron23 today announced the publication of a manuscript in the Proceedings of...
Read More
Portfolio News

Neuron23 to Present Phase 1 Healthy Volunteer Data of NEU-411, a Brain-penetrant LRRK2 Inhibitor, at AD/PD™ 2025

March 24, 2025
Data from the Phase 1 healthy volunteer study of NEU-411 will...
Read More
Portfolio News

Latigo Biotherapeutics Closes $150 Million in Series B Financing to Advance Non-Opioid Pain Therapeutics

March 17, 2025
Financing led by funds managed by Blue Owl Capital; Senior Managing...
Read More
Portfolio News

Latigo Biotherapeutics Granted FDA Fast Track Designation for LTG-001, Potential Best-in-Class Nav1.8 Inhibitor for the Non-Opioid Treatment of Acute Pain

March 3, 2025
LTG-001 demonstrated favorable safety and tolerability profile with predictable pharmacokinetics in...
Read More
Portfolio News

Capsida Announces AbbVie Opt-in for First Genetic Medicine Program from Neurodegenerative Disease Collaboration

January 7, 2025
Capsida to receive a $40 million license payment and is eligible...
Read More
Portfolio News

Borealis Biosciences Appoints Christian Hordo as CEO and Expands Series A Financing

December 19, 2024
Westlake BioPartners leads $30 million Series A extension, bringing the startup’s...
Read More
Portfolio News

Subscribe to Stay Current

    • People
    • Portfolio
    • About
    • News
    • Contact

    © 2025 Westlake BioPartners. All Rights Reserved. Privacy Policy